Stuart Varney introduces the new Lyme disease vaccine developed by Pfizer and Valneva, highlighting it as the first human vaccine for the disease in decades. Dr. Marc Siegel confirms the vaccine's 70% effectiveness in Phase 3 trials and an estimated approval in 2027, despite some challenges in accumulating sufficient infection data.